BAKX Therapeutics is a New York and Boston based company focused on developing safer, more effective therapeutics that fully realize the potential of the mitochondrial apoptosis pathways. BAKX was co-founded by world leading researchers in the field of apoptosis and computationally aided drug discovery. The company's leading asset BKX-001 (partnered with Ipsen) is focused on targeting the BAX protein. In addition, the BAKX platform is deployed towards drugging other undisclosed apoptosis targets implicated in various solid tumors and the build up of resistance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/18/21 | $25,000,000 | Series A |
AB Magnitude Ventures Group Ipsen Sherpa Healthcare Partners | undisclosed |
